Document is current

Article History

Accepted: 11 October 2022

First Online: 29 November 2022

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees/Institutional Review Boards of all participating sites.

: Informed consent was obtained from all individual participants included in the study.

: Roy O. Mathew, MD: No relevant disclosures.Mandeep S. Sidhu, MD, MBA: Astra Zeneca 2019 SAB, Sanofi-Regeneron 2019 SAB.Michael E. Farkouh, MD: research support from Amen, Novartis and Novo Nordisk.Charanjit S. Rihal, MD: No disclosures.Ryan Lennon, MS: No disclosures.Mohammad El-Hajjar, MD: No disclosures.Neil Yager, DO: No disclosures.Radmila Lyubarova, MD: No disclosures.Yves Rosenberg, MD: No disclosures.Khaled Abdul-Nour, MD: No disclosures.Steven Weitz, MD: No disclosures.D. Fearghas O’Cochlain, MD: No disclosures.Vishu Murthy, MD: No disclosures.Justin Levisay, MD: Previous proctoring relationship with Boston Scientific which has ceased with the Lotus valve being pulled from the Market.Kevin Marzo, MD: No disclosures.John J. Graham, MD: Honoraria: Astra Zeneca, Teleflex Medical, Boston Scientific.Vladimír Džavík, MD: No relevant disclosures.Derek So, MD: He has received unrestricted grant support (physician-initiated grant) from Eli Lilly Canada; is a member of the advisory board and has received honoraria from AstraZeneca Canada; is a member of the advisory board for Bayer Canada; has received unrestricted grant support (physician-initiated grant) from Spartan Biosciences; has received unrestricted grant support (physician-initiated grant) from Aggredyne; and has received unrestricted grant support (physician-initiated grant) from Diapharma/Roche Diagnostics.Shaun Goodman, MD: Shaun G. Goodman reports research grant support (e.g., steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (e.g., advisory boards) from: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health).Naveen Pereira, MD: Funding for this research was provided by the NIH (grants U01HL128606 and U01HL128626).

: Its contents are solely the responsibility of the authors and do not necessarily represent official views of the Department of Veterans Affairs, National Heart, Lung, and Blood Institute, the National Institutes of Health, or the Department of Health and Human Services. Parts of this manuscript were presented as a recorded abstract for the American College of Cardiology Scientific Session 2021.